




Fig. S2







aberrant transcript (403bp):


--T--R--I--M--D--E--R--N--R--Q--V--S--H--A--D--R--K--E--P--K--N--T--S--F--T--Q--


 ${\tt cttgatgggttgttttagacagaaatagatcaa {\tt GACATTTACAAAGAGAAAGTTTGGCCTGATGAAGAAAGCCTACGA}$

A--*-

GCTGAGCGTGTTGTGTGACTGTGAGATTGCCCTGATCATCTTCAACAGCACCAACAAGCTGTTCCAGTACGCCAGCACAG ATATGGACAAAGTGCTGCTCAAATACACAGAGTACAACGAGCCACACGAGGAGCAGGACCAACTCGGACATAGTGGAGACC CTGAGAAAGAAGGGTCTAAATGGCTGTGACAGCCCGGACCCCGACGCCGACGACTCGGTGGG<u>CCACAGCCCAGAGTCAAA</u>

Fig. S4





Fi	q.	S	6


A	sib	mef2ca ^{b1086} ;mef2cb ^{fh288}					
myl7		-	*				

В	con	mef2ca MO	<i>mef2cb</i> ^{fh288/+} incross	sib + <i>mef2ca</i> MO	<i>mef2cb^{fh288} +mef2ca</i> MO
myl7				3	A

С	sib <i>+mef2ca</i> MO	<i>mef2cb</i> ^{fh288} + <i>mef2ca</i> MO
bright field		

	con	hand2 MO
Α	A State Mary	22s
mef2ca	* *	* *
mef2cb U	* *	

Fig. S8






Table S1 Quantification of effects of loss- and gain-of-function.

Fig. No.		con	mef2ca MO	mef2cb MO	mef2ca+ mef2cb MO	<i>mef2ca^{+/b1086}</i> incross	<i>mef2ca^{+/b1086}</i> incross+ <i>mef2cb</i> MO	<i>mef2c^{+/tn213}</i> incross	mef2ca ^{+/tn213} incross+ mef2cb MO	mef2d/c MO	<i>mef2d</i> MO	<i>mef2cb^{+/fh288}</i> incross	<i>mef2cb^{+/fh288}</i> incross + <i>mef2ca</i> MO	<i>mef2ca^{+/b1086};</i> <i>mef2cb^{+/fh288}</i> incross
2A-F, S5A	<i>myl7</i> 15s	87/87 (100%) n	11/41 (27%) n, 30/41 (73%) r	39/39 (100%) n	7/17 (41%) n, 10/17 (59%) a	30/37 (81%) n, 7/37 (29%) r	44/57 (77%) n, 13/57(23%) a	30/45 (67%) n, 15/45 (33%) r,		5/27 (18%) sr, 22/27 (82%) a	21/21 (100%) n	19/19 (100%) n		58/62 (94%) n, 4/62(6%) a
2A-F, S5B	vmhc 15s	135/135 (100%) n		42/42 (100%) n		26/26 (100%) n	22/31 (71%) n, 9/31 (29%) a	22/33 (66%) n, 11/33 (34%) r,	8/46 (17%) n, 22/46 (48%) r, 16/46 (35%) a	4/65 (6%) n, 1/65 (2%) r, 60/65 (92%) a		20/20 (100%) n		79/86 (92%) n, 7/86 (8%) a
2A-D	smyd1b 13s	98/98 (100%) n		65/65 (100%) n		12/46 (26%) n, 23/46 (50%) r, 11/46 (24%) a	49/64 (77%) n, 15/64 (23%) a	7/31 (22%) n, 15/31 (48%) r, 9/31 (30%) a		3/67 (4%) n, 2/67 (3%) r, 62/67 (93%) a (in heart)				
2A-D	smyd1b 17s	28/28 (100%) n		25/25 (100%) n		21/22 (95%) n, 1/22 (5%) r	17/21 (81%) n, 4/21 (19%) a			13/55 (24%) n, 16/55 (29%) r, 26/55 (47%) a (in heart)				
2G	MyHC 24s									u (m neur)				94/107 (87%) n, 6/107 (6%) r, 7/107 (7%) a
3A-F	MyHC 24 hpf	25/25 (100%) n		8/26 (31%) n, 18/26 (69%) sm				+/+*: 10/12 (83%) n, 2/12(17%) r +/ <i>tn213*</i> : 28/28 (100%) n <i>tn213/tn213*</i> : 15/19 (79%) n, 4/19 (21%) r	+/+*: 5/19 (26%) n, 14/19(84%) r +/m213*: 9/35 (26%) n, 25/35 (71%) r, 1/35 (3%) a <u>m213/m213*:</u> 1/17 (6%) n, 16/17 (94%) a			31/31 (100%) n		74/80 (93%) n, 6/80 (7%) res
3A-F	<i>bmp4</i> 24 hpf	23/23 (100%) n		1/22 (4%) n, 21/22 (96%) sm		27/27 (100%)	16/23 (70%) sm, 7/23 (30%) a					53/53 (100%) n		83/88 (94%) n, 5/88 (6%) res
3A-F, S6A,B	<i>myl7</i> + <i>vmhc</i> 24 hpf or: <i>myl7</i> only	122/128 (95%) n, 6/128 (5%) r <u>myl7 only:</u> 48/48 (100%) n	<u>myl7 only:</u> 56/56 (100%) n	16/33 (48%) n, 17/33 (52%) sm		49/49 (100%) n	3/59 (5%) n, 41/59 (69%) r, 15/59 (26%) a			3/36 (8%) n, 33/36 (92%) a		36/36 (100%) n <u>myl7 only:</u> 78/78 (100%) n	<u>myl7 only:</u> 58/80 (72%) n, 22/80 (28%) sr	83/86 (96%) n, 3/86 (4%) res <u>myl7 only:</u> 71/79 (90%) n, 8/79 (10%) res
3G	<i>acta1b</i> 24 hpf	22/22 (100%) n	(((((((((((((((((((((((((((((((((((((((4/28 (14%) n, 10/28 (36%) r, 14/28 (50%) a				
3Н	<i>tnnc2</i> 24 hpf	25/25 (100%) n	23/23 (100%) n							3/25 (12%) n, 22/25 (30%) a	24/24 (100%) n			
31	<i>mybpc1</i> 24 hpf	38/38 (100%) n 16/16								6/41 (14%) n, 35/41 (86%)				
3J 4A, S6C	nppa 24 hpf Bright field 48-72 hpf	(100%) n								5/21 (23%) n, 16/21 (77%) a		158/158 (100%) n	106/146 (73%) n, 40/146 (27%)	642/694 (93%) n, 52/694 (7%)
4B	myl7 +vmhc												sr + edema,	a or res + edema, 69/74 (93%) n, 5/74 (7%) res
4C	48 hpf MyHC +Mef2,													80/83 (96%) n, 3/83 (4%) res
4D	50 hpf MyHC (A4.1025); S46, 48 hpf	15/15 (100%) n								1/26 (4%) n, 6/26 (23%) sr, 19/26 (73%) a				
4E	<i>nppa</i> 48 hpf													52/55 (95%) n, 3/55 (5%) res
4F	<i>myl7</i> + <i>bmp4</i> 48 hpf													46/50 (92%) n, 4/50 (8%) res
4G														73/78 (94%) n, 5/78 (6%) res

Fig. No.		con	mef2ca MO	mef2cb MO	mef2ca+ mef2cb MO	<i>mef2ca^{+/b1086}</i> incross	mef2ca ^{+/b1086} incross+ mef2cb MO	<i>mef2c^{+/m213}</i> incross	<i>mef2ca^{+/m213}</i> incross+ <i>mef2cb</i> MO	mef2d/c MO	mef2d MO	<i>mef2cb^{+/fh288}</i> incross	<i>mef2cb^{+/fh288}</i> incross + <i>mef2ca</i> MO	<i>mef2ca^{+/b1086};</i> <i>mef2cb^{+//h288}</i> incross
5A	nkx2.5 12s	27/27 (100%) n			22/22 (100%) n									60/60 (100%) n
5B	hand2 12s	16/16 (100%) n			24/24 (100%) n									68/68 (100%) n
5C	gata4 12s	20/20 (100%) n			27/27 (100%) n									70/70 (100%) n
5D	123 tbx20 22s	13/13 (100%) n								22/22 (100%) n (but loss of ring shape)				
5E	gata6 (±myl7) 22s	22/22 (100%) n								3/26 (11%) n, 23/26 (89%) n (but loss of ring shape)				57/61 (93%) n, 4/61 (7%) a <i>myl7</i> ; loss of ring shape <i>gata6</i>
5F	nkx2.5 (±myl7) 22s	46/46 (100%) n,	46/46 (100%) n	15/40 (37%) 16/40 (40%) 9/40 (13%)	r,					8/57 (14%) n, 49/57 (86%) sr,				55/58 (95%) n, 3/58 (5%) a myl7 res nkx2.5
5G	<i>hand2</i> 20-25s	15/15 (100%) n						34/34 (100%) n	13/49 (27%) n, 36/49 (73%) up	16/16 (100%) up				58/62 (94%) n, 4/62 (6%) up
5H	<i>cdh5;myl7</i> 22s	68/68 (100%) n								21/65 (32%) n, 44/65 (68%) sr or a <i>myl7</i> ; up and expanded <i>cdh5</i>				79/85 (93%) n, 6/85 (7%) a <i>myl7</i> ; up and expanded <i>cdh5</i>
51	<i>cdh5;myl7</i> 48 hpf													87/92 (95%) n, 5/92 (5%) res <i>myl7</i> ; up and expanded <i>cdh5</i>
		con	mef2c	b BAC DNA	mef2cb mRNA	mef2cb ^{+/fh288} incross								
5A, 51G	MyHC; Mef2ca/cb 24 hpf	20/20 (100%) 1	n		5/22 (22%) n, 17/22 (78%) up+ectopic									
6B	smyd1b 24 hpf	25/25 (100%) t	n		5/23 (22%) n, 18/23 (78%) up+ectopic									
6C	24 hpf 24 hpf	19/19 (100%) t	n		13/37 (35%) n, 24/37 (65%) up (in			-						
6D	<i>myod;myl7</i> 14s	9/9 (100%) n			cardiac region) 5/22 (23%) n, 17/22 (77%) ectopic myod, no myl7			-						
6E	<i>myod;myl7</i> 24s	11/11 (100%) 1	n		5/16 (31%) n, 10/16 (78%) ectopic myod, reduced myl7									
6F	<i>myl7;cdh5</i> 24s	14/14 (100%) 1	n		5/24 (21%) n, 19/24 (79%) reduced <i>myl7</i> reduced <i>cdh5</i>									
6G	<i>myl7</i> 24 hpf	24/24 (100%) t	n 24/41 17/41	(58%) n, (42%) ect										
7A	myl7+vmhc, 50 hpf		1//41			51/51 (100%) i 12 genotyped	n;	1						
7B	bmp4 48 hpf					42/42 (100%) 1 12 genotyped		1						
7C	Zn-5+Elastin, 72 hpf					38/38 (100%) 1 12 genotyped	n;]						
S1A-D	<i>mef2cb</i> 24 hpf			(73%) up in ric distribution										
		con	mef2cb N	40 /	<i>nef2ca^{b1086}</i> incross	mef2d/c MO		<i>mef2ca</i> ^{tn213} incross			<i>mef.</i> incr	2ca ^{+/b1086} ; mef2cb ^{+/fh288}		
S2B,C	Mef2ca/cb			9	29/38 (76%) n 9/38 (24%) a (somite), sr heart)									
S4B	<i>kdrl (± myl7)</i> 21s	16/16 (100%) n	,		nourt)	29/29 (100%) n		1				41/4	4 (93%) n, 3/44 (7%) a	myl7; n kdrl
S4D	21s fli1:GFP 24 hpf	(100%) n 23/23 (100%) n				18/18 (100%) n (ł	heart region)							
S4E	cdh5 24 hpf	26/26 (100%) n				6/21 (27%) n, 15/21 (73%) up								
S5A	myl7		y for 2A-F			15/21 (1570) up		1				I		

S5B	vmhc 15s	See entry for 2A-F											
		con	mef2cb MO	<i>mef2ca^{b1086}</i> incros	is	mef2d/c MO	<i>mef2ca^{tn213}</i> incross	hand2 MO	<i>mef2ca^{+/b1086}; mef2cb^{+//b288}</i> incross				
S5C	<i>bmp4</i> 22s	35/35 (100%) n				15/79 (19%) n, 19/79 (24%) r, 45/79 (57%) sr							
S5D	smyd1b 22s	41/41 (100%) n				36/36 (100%) a							
S5E	gata4 12s	21/21 (100%) n				35/35 (100%) n							
S5E	gata5 12s	26/26 (100%) n				26/26 (100%) n							
S5E	gata6 12s	24/24 (100%) n				24/24 (100%) n							
S6A,B	<i>myl7</i> 24 hpf	See entry for 3.	A-F				L		I				
S6C	Bright field phenotype	See entry for 4.	A										
S7A	mef2ca 22s	23/23 (100%) n						18/19 (94%) cb (nl) 1/19 (6%) n					
S7B	mef2cb 22s	31/31 (100%) n						23/24 (96%) cb (nl) 1/24 (4%) n					
S8A	<i>myl7+vmhc</i> 48 hpf						29/29 (100%) n**						
S8B	<i>myl7</i> + <i>bmp4</i> 48 hpf						36/36 (100%) n**						
S8A	<i>smyd1b</i> 24 hpf	53/53 (100%) n	5/32 (15%) n, 27/32 (85%) sm, up										
S9A	<i>myl7</i> 48 hpf	25/25 (100%) n	7/77 (9%) 70/77 (91%) small, unlooped heart										
S9B	<i>bmp4</i> 48 hpf	24/24 (100%) n	7/48 (15%) n, 41/48 (85%) up, unlooped heart										
S9D	MF20; DAF-2DA 72 hpf	12/12 (100%) n	2/14 (14%) n, 12/14 (86%) a										
		mef2ca ^{b1086} ; Tg(myl7:GFP; myl7;ndsRed)	Tg (myl7:GFP)	Tg (myl7:GFP) + mef2cb MO	Tg (myl7:GF mef2ca MO	P) + mef2ca ^{b1086} ; Tg(myl7:GFP)							
S8C, S9C	<i>myl7:GFP;</i> Elastin,72 hpf		12/12 (100%) n	3/15 (20%) n, 2/15 (43%) r, 10/15 (67%) a	8/10 (80%) n 2/10 (20%) r	12/12 (100%) n**							
S8D	myl7:GFP; myl7:ndsRed, 60 hpf	21/21 (100%) n**											

Fraction of embryos showing normal, or any deviated effect of mRNA expression, protein immunodetection or marker at the indicated stages. Abbreviations: n, normal, ab, abnormal, r, reduced, sr, strongly reduced, res, absent except for a few residual cells, up, upregulated, a, absent, sm, small heart, cb, cardia bifida, nl, normal levels * genotype verified by Mef2C immunostaining. ** Results verified by sequence genotyping.